USA-based biopharma firm Ampio Pharmaceuticals (Nasdaq: AMPE) has announced positive results from its study of Ampion for the treatment of osteoarthritis of the knee (OAK).
Ampion is a new molecular entity being developed as a non-steroidal injection and oral drug for the treatment of diseases involving inflammation. In a Phase III trial patients receiving Ampion experienced, on average, a greater than 40% reduction in pain from baseline.
Study details
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze